Abstract 400P
Background
Breast cancer is the leading killer of female cancer patient. Lung cancer became the second affecting cancer (12%) but the main killer (25%) in female cancer patient. (Cancer fact and Figures 2017” report published by American Cancer Society) and odd of getting lung cancer are 1 in 17. In Bangladesh, the status and features of female lung cancer is not clear. In western country, female are more prone to lung cancer due to some risk factor like smoking, alcohol, exposure of radon etc than Bangladesh. We tried to find out the socio-demographic status and clinical features of lung cancer of female in Bangladesh.
Methods
This was a descriptive comparative observational study on 2396 female cancer patients reached at Outpatient of Medical oncology department of National Institute of cancer Research and Hospital, Mohakhali, Bangladesh from January 2018 to December 2018. Patients were selected purposive sampling method.
Results
Total number of 2396 female patients were included in this study. The average age of female lung cancer patient was 56.12 years and average weight was 45.32kg. We had found 336 lung cancer patients (14%) among the 2396 female cancer patient. 58% were adenocarcinoma, 26% were Squamous Cell, 7% small cell variety with undifferentiated and others like Sarcoma, mesothelioma etc were 9%. Most of the patients were illiterate (59%) and 79% patient were poor or below average economically. 42% female patient didn’t have any habitual problem. 46.82%% patients had the battle nut/ Jarda, 7.65% were smoker, about 10% had more than one habitual issue. At the time of presentation none of the had ECOG 0, patients had performance status O, most of the patient’s performance status (ECOG) were 1 (58%) ECOG2 were 27%. 39% patient had comorbidity, among them most frequent comorbidity was Hypertension which was 39% and second was DM (33%) and 20% patient having more than one comorbidity.
Conclusions
The percentage of female lung cancer in Bangladesh is pretty high among female cancer patient. female are most vulnerable group in rural area as well as they need special attention. Moreover, female lung cancer with other comorbidities makes the treatment more complicated for the cancer physician as well as brings the worst outcome. So, female lung cancer management should be personalized and comprehensive.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract